**Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.